REGENXBIO, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US75901B1070
USD
12.98
0.77 (6.31%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Keros Therapeutics, Inc.
Innoviva, Inc.
Collegium Pharmaceutical, Inc.
Ardelyx, Inc.
REGENXBIO, Inc.
Revance Therapeutics, Inc.
Morphic Holding, Inc.
Pharvaris NV
ACELYRIN, Inc.
POINT Biopharma Global, Inc.
Intercept Pharmaceuticals, Inc.
Why is REGENXBIO, Inc. ?
1
Poor Management Efficiency with a low ROE of 3.20%
  • The company has been able to generate a Return on Equity (avg) of 3.20% signifying low profitability per unit of shareholders funds
2
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 40.40%, its profits have risen by 38.9%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is REGENXBIO, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
REGENXBIO, Inc.
39.57%
-0.02
84.86%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
20.75%
EBIT Growth (5y)
-1.16%
EBIT to Interest (avg)
-15.16
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.75
Sales to Capital Employed (avg)
0.27
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
97.82%
ROCE (avg)
9.52%
ROE (avg)
3.20%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.76
EV to EBIT
-1.75
EV to EBITDA
-1.95
EV to Capital Employed
4.06
EV to Sales
1.76
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-231.58%
ROE (Latest)
-57.51%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

19What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -87.88 MM

NET SALES(HY)

Higher at USD 110.37 MM

NET PROFIT(HY)

Higher at USD -64.79 MM

RAW MATERIAL COST(Y)

Fallen by -68.75% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 6.82 times

-26What is not working for the Company
NET SALES(Q)

At USD 21.36 MM has Fallen at -45.48%

DEBT-EQUITY RATIO (HY)

Highest at -24.15 %

INTEREST(Q)

Highest at USD 10.99 MM

OPERATING PROFIT(Q)

Lowest at USD -59.37 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -277.98 %

PRE-TAX PROFIT(Q)

Lowest at USD -70.87 MM

NET PROFIT(Q)

Lowest at USD -70.87 MM

EPS(Q)

Lowest at USD -1.38

Here's what is working for REGENXBIO, Inc.
Operating Cash Flow
Highest at USD -87.88 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Debtors Turnover Ratio
Highest at 6.82 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by -68.75% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for REGENXBIO, Inc.
Net Sales
At USD 21.36 MM has Fallen at -45.48%
over average net sales of the previous four periods of USD 39.18 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit
At USD -70.87 MM has Fallen at -79.77%
over average net sales of the previous four periods of USD -39.42 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit
At USD -70.87 MM has Fallen at -79.77%
over average net sales of the previous four periods of USD -39.42 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Interest
At USD 10.99 MM has Grown at 28.27%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Interest
Highest at USD 10.99 MM
in the last five periods and Increased by 28.27% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Profit
Lowest at USD -59.37 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (USD MM)

Operating Profit Margin
Lowest at -277.98 %
in the last five periods
MOJO Watch
Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit
Lowest at USD -70.87 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit
Lowest at USD -70.87 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

EPS
Lowest at USD -1.38
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Debt-Equity Ratio
Highest at -24.15 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio